Is it the Right Time to Retain Abbott Stock in Your Portfolio?

Abbott (ABT) demonstrates robust operational strength, with its Nutrition business achieving 3.4% organic growth in Q2 2025 and the FreeStyle Libre CGM system driving 19.6% organic growth in Diabetes Care, bolstered by recent FDA approvals for new over-the-counter versions. The Established Pharmaceuticals division also posted 7.7% organic growth in emerging markets, underpinned by a strategic focus on biosimilars. Despite these core business tailwinds, the company faces headwinds from macroeconomic challenges, which are impacting margins through increased expenses, and adverse foreign currency fluctuations, resulting in a 1.1% unfavorable impact on H1 2025 sales. ABT's stock has outperformed its industry, rallying 17.5% over the past year, reflecting investor confidence in its growth drivers despite external pressures.

Analysis

Abbott Laboratories (ABT) is demonstrating robust growth in its core segments, offsetting significant macroeconomic and currency headwinds. The Diabetes Care division remains a key performance driver, with the FreeStyle Libre platform achieving 19.6% organic sales growth in Q2 2025, exceeding $1.9 billion, and an even stronger 26% growth in the United States. The recent FDA approvals for over-the-counter CGM systems, Lingo and Libre Rio, represent a major catalyst by expanding the addressable market. The Established Pharmaceuticals Division (EPD) also shows sustained momentum in emerging markets, posting 7.7% organic growth and a five-year CAGR of 8%, with a biosimilar pipeline set for 2026 launches. The Nutrition business is recovering, with 3.4% organic growth driven by a 6.6% increase in Adult Nutrition. However, these strong operational results are tempered by external pressures. The company faces margin compression from rising raw material and freight costs and a notable 1.1% unfavorable sales impact from foreign exchange in the first half of 2025. Despite these challenges and a Zacks 'Hold' rating, the stock's 17.5% rally over the past year indicates that investors are currently prioritizing the company's strong market share gains and innovation pipeline over the prevailing headwinds.

Key Decisions for Investors

• Investors should recognize that Abbott's primary value driver is the Diabetes Care segment, where the 19.6% organic growth of FreeStyle Libre and recent over-the-counter FDA approvals signal a strong, expanding market position.
• It is critical to monitor the impact of macroeconomic pressures on operating margins and the persistent drag from foreign exchange, which trimmed 1.1% from H1 2025 sales, as these are the primary risks to near-term earnings.
• Given the stock's outperformance against its industry and the stable consensus earnings estimate of $5.15 for 2025, a 'Hold' strategy is defensible, but any upward revisions to earnings guidance could serve as a key catalyst for further appreciation.
• Consider the long-term growth potential from the Established Pharmaceuticals Division, whose 7.7% organic growth in emerging markets and strategic pivot to biosimilars provide a geographically diversified revenue stream.